FDA Grants Priority Review Status to Cholera Vaccine

FDA News reports that FDA has granted priority review status to PaxVax’s single-dose cholera vaccine Vaxchora.

The Agency has identified cholera as one of the eligible neglected tropical diseases under its priority review voucher program. The potential of being granted a voucher was a significant incentive for PaxVax to develop the vaccine for the U.S. market, the company says.